NEWS 11
ausdoc . com . au 14 JUNE 2024
NEWS 11
‘ Patient used 500 nangs a day ’
|
Antony Scholefield NITROUS oxide abuse is causing
severe symptoms , from psychosis
to spinal cord degenera-
|
But a female patient , also in her 20s , presented with ataxia , urinary retention and auditory hallucinations after using 50 |
predominantly in the cervical spine , in 12 patients .
Only four individuals responded to follow-up
|
presentations to ED with complications from high chronic use , viz sub-acute combined degeneration of the spinal |
|
committee recommended a complete ban , but the commercial use of N 2
O for food preparation meant the regula-
|
tion , ED doctors report in a case |
bulbs a day for several months , |
after three months , of whom |
cord , that results in perma- |
tor instead opted to mandate |
series of 22 Australian patients . |
the authors said . |
three had ongoing paraesthe- |
nent disability and is costly to |
warning labels and restrict |
Colloquially known as |
She remained in hospital for |
sia , mobility problems and |
the health system ,” they wrote |
sales to over-15s from 2022 . |
|
‘ nangs ’, bulbs of nitrous oxide ( N 2
O ) are designed for whipping cream and available for under $ 1
|
31 days for treatment with vitamin B12 , methionine and folate — at an estimated health system |
impaired fine motor skills . The authors said N 2
O abuse was not considered a
|
in Drug and Alcohol Review . The team said they provided their data to the TGA |
States and territories have also implemented their own rules , with the WA Govern- |
|
per canister .
But inhalation provides users with a seconds-long high , and despite the potential for neuro-
|
cost of $ 290,000 .
The doctors also found MRI-confirmed sub-acute combined degeneration ,
|
significant health concern “ historically ”.
“[ There has been ] a notable increase in the number of
|
when it was weighing up tougher controls on N 2
O canisters in 2021 . The TGA ’ s expert
|
ment set to restrict sales to registered food and beverage businesses later this year . Drug Alcohol Rev 2024 ; 13 May . |
logical damage , recreational use |
|
|
|
|
is increasing . |
|
|
|
|
Clinicians at the Royal |
|
|
|
|
|
Perth Hospital reviewed all
N 2
O-related ED presentations between June 2019 and June 2021 .
Eighteen out of 22 patients reported ataxia , paraesthesia and falls ; however , the overall range
|
|
|
|
LOWEST LDL-C IS BEST * 1 , 2
Learn more at beyondstatins . com . au
|
and severity of symptoms varied |
|
|
|
|
|
greatly .
For instance , a man in his 20s who used 500 bulbs a day for half
|
|
|
|
* There is a linear association between lower LDL-C and lower CV risk in secondary prevention studies , with no lower limit for the association ( or ‘ J-curve ’ effect ). 1 , 2 |
a week reported hyperemesis as |
|
|
|
|
his only symptom and was discharged |
|
|
|
|
after two days following |
|
|
|
|
vitamin B12 administration . |
|
|
|
|
Blur the bedroom consult |
|
|
|
|
Carmel Sparke DO not carry out video consults in the bedroom — that is the main finding from a study on the best background for telehealth .
Based on a survey of 1200 adults , it found that patients rated doctors with visible certificates as more knowledgeable , trustworthy and caring .
And two-thirds preferred to view their doctor in an office setting , with those displaying diplomas ranking the highest .
This setting also scored the highest when patients were asked to rank how knowledgeable , trustworthy , caring , approachable and professional a doctor appeared .
The next best option was a doctor ’ s office without certificates — preferred by 18 % of patients — or an exam room , home office or solid-colour background , which were each preferred by about 14 % of patients .
If doctors had to conduct a video telehealth consult from a bedroom or kitchen , the results suggested that blurring the background would be a good idea .
These settings were preferred by just 3.5 % and 2 % of patients , respectively , the researchers reported in a research letter published in JAMA Network Open .
Lead author Associate Professor Nathan Houchens , an internal medicine specialist at the University of Michigan , said the team was surprised by the level of dislike that patients had for kitchen and bedroom backgrounds . JAMA Netw Open 2024 ; 15 May .
PREVENT
†
ANOTHER CV EVENT † 3 , 4
Repatha ® is indicated for the prevention of CV events ( MI , stroke and coronary revascularisation ) in adults with established CV disease in combination with an optimally dosed statin and / or other lipid-lowering therapies , as an adjunct to diet and exercise . 3
‘ Power ’: 15 % relative risk reduction with Repatha ® vs placebo in the composite of the primary endpoint beyond optimised statin ± ezetimibe ( HR : 0.85 ; 95 % CI : 0.79 – 0.92 , p < 0.001 ). 4
PBS Information : Authority Required . Non-familial and familial hypercholesterolaemia . Criteria apply for certain patient populations . Refer to PBS Schedule for full Authority Required Information .
Refer to full Product Information before prescribing ; available from Amgen Australia Pty Ltd , Ph : 1800 803 638 or by scanning the QR code : For more information on Repatha ® or to report an adverse event or product complaint involving Repatha ® , please contact Amgen Medical Information on 1800 803 638 or visit www . amgenmedinfo . com . au .
Precautions : Hypersensitivity reactions . Concomitant lipid lowering therapies – check all relevant prescribing information . Effects of long-term very low LDL-C levels are unknown . Immunogenic potential . Pregnancy Category : B1 . Caution – breastfeeding . Adverse Reactions : Common – nasopharyngitis , upper respiratory tract infection , influenza , back pain , arthralgia , nausea , rash , and injection site reactions ( including injection site pain , erythema , bruising , swelling or haemorrhage ).
Abbreviations : CI , confidence interval ; CV , cardiovascular ; HR , hazard ratio ; LDL-C , low-density lipoprotein cholesterol ; MI , myocardial infarction ; PBS , Pharmaceutical Benefits Scheme .
References : 1 . Mach F , et al . Eur Heart J 2020 ; 41 ( 1 ): 111 – 188 . 2 . Packard C , et al . Heart 2021 ; 107:1369 – 1375 . 3 . Repatha ® ( evolocumab ) product information . 4 . Sabatine MS , et al . N Engl J Med 2017 ; 376:1713 – 1722 .
Amgen Australia Pty Ltd . ABN 31 051 057 428 , Sydney NSW 2000 . © 2024 Amgen Inc . All rights reserved . AUS-145-0124-80028 . AMG8657 . Date of preparation : February 2024
† 3,4
AMG8657 _ Repatha Print Media 24 _ Aus Doc _ A4 _ 210x273 _( MALE )_ V0.4 _ FA . indd 1 5 / 2 / 2024 3:31 pm